3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.

Chris Parker,Sten Nilsson,Nicholas J Vogelzang,Robert E Coleman ,A Oliver Sartor ,Mona Wahba ,David Bottomley ,Irene Skjørestad

doi:10.1200/jco.2015.33.15_suppl.e16102

3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.

Chris Parker, Sten Nilsson + Show 6 more

https://doi.org/10.1200/jco.2015.33.15_suppl.e16102

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2015
Citations: 2

Affiliation: Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Karolinska University Hospital, Comprehensive Cancer Centers of Nevada, Weston Park Cancer Centre, Tulane University, Bayer (United States), St James's University Hospital, Bayer (Norway)

#Symptomatic Bone Metastases #ALSYMPCA Study + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

5070 Background: Ra-223, an alpha-emitting pharmaceutical, significantly improved overall survival and was well tolerated in ALSYMPCA (Parker, NEJM2013). Long-term safety monitoring of Ra-223 is es...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.